[go: up one dir, main page]

MX2009008413A - Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica. - Google Patents

Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica.

Info

Publication number
MX2009008413A
MX2009008413A MX2009008413A MX2009008413A MX2009008413A MX 2009008413 A MX2009008413 A MX 2009008413A MX 2009008413 A MX2009008413 A MX 2009008413A MX 2009008413 A MX2009008413 A MX 2009008413A MX 2009008413 A MX2009008413 A MX 2009008413A
Authority
MX
Mexico
Prior art keywords
compositions
prevention
treatment
administered
immune response
Prior art date
Application number
MX2009008413A
Other languages
English (en)
Inventor
Tai June Yoo
Original Assignee
Tai June Yoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tai June Yoo filed Critical Tai June Yoo
Publication of MX2009008413A publication Critical patent/MX2009008413A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En este documento se proporcionan composiciones y métodos para tratar y/o prevenir una enfermedad neurodegenerativa, tal como enfermedad de Alzheimer. En aspectos particulares, las composiciones administradas en este documento codifican un elemento de respuesta inmune celular. Las composiciones pueden prepararse y administrarse de manera tal que la secuencia codificante del elemento de respuesta inmune celular se expresa en el sujeto al que se administra la composición. Las composiciones incluyen sistemas de expresión, sistemas de suministro, y ciertos genes de elementos de respuesta inmune celular.
MX2009008413A 2007-02-06 2008-02-04 Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica. MX2009008413A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90013807P 2007-02-06 2007-02-06
PCT/US2008/052953 WO2008097927A2 (en) 2007-02-06 2008-02-04 Treatment and prevention of neurodegenerative diseases using gene therapy

Publications (1)

Publication Number Publication Date
MX2009008413A true MX2009008413A (es) 2009-11-02

Family

ID=39682371

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008413A MX2009008413A (es) 2007-02-06 2008-02-04 Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica.

Country Status (13)

Country Link
US (2) US8247385B2 (es)
EP (1) EP2114153B1 (es)
JP (1) JP5829377B2 (es)
KR (2) KR20140102327A (es)
CN (2) CN101652063A (es)
AU (1) AU2008213999B2 (es)
CA (1) CA2677273A1 (es)
IL (1) IL200151A (es)
MX (1) MX2009008413A (es)
NZ (1) NZ579050A (es)
RU (1) RU2471487C2 (es)
WO (1) WO2008097927A2 (es)
ZA (1) ZA200906165B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010110408A1 (ja) * 2009-03-26 2010-09-30 財団法人東京都医学研究機構 アルツハイマー病に対するdnaワクチン
US9173928B2 (en) 2009-03-26 2015-11-03 Yoh Matsumoto DNA vaccine for Alzheimer's disease
KR101367568B1 (ko) * 2011-05-31 2014-02-27 임우석 Ａｂｃ 수송체 조절을 통한 퇴행성신경질환에서 이상단백질 조절
US20160058889A1 (en) * 2014-08-11 2016-03-03 The Board Of Regents Of The University Of Texas System Prevention of muscular dystrophy by crispr/cas9-mediated gene editing
RU2652312C2 (ru) * 2016-01-20 2018-04-25 Селл энд Джин Терапи Лтд Линейка биологически активных генно-терапевтических субстанций на основе гена tgfb1 для коррекции патологических состояний клеток органов и тканей и органов и тканей человека, способ получения и использования
CN105748518B (zh) * 2016-03-21 2019-06-07 大连大学 包含脂肪干细胞提取物的抗衰老组合物
CA3031401A1 (en) * 2016-07-20 2018-01-25 Vib Vzw Therapeutic agents for neurological and psychiatric disorders
CA3051583A1 (en) 2017-01-25 2018-08-02 Whitehead Institute For Biomedical Research Methods for building genomic networks and uses thereof
WO2019147036A1 (ko) * 2018-01-24 2019-08-01 주식회사 에스엘바이젠 뇌유래-신경영양인자를 발현하는 중간엽줄기세포 및 이의 용도
WO2019162942A1 (en) * 2018-02-20 2019-08-29 Carmel Haifa University Economic Corporation Ltd. Compositions and methods for delivery and expression of small inhibitory peptides and use thereof
IT201800003279A1 (it) * 2018-03-05 2019-09-05 Consiglio Nazionale Ricerche Peptide neurotrofico per il trattamento terapeutico di patologie neurodegenerative e/o infiammatorie.
CN109942714B (zh) * 2019-04-02 2022-07-08 中国药科大学 一种功能多肽及应用
WO2020212598A1 (en) 2019-04-19 2020-10-22 Synerkine Pharma B.V. A fusion protein comprising il13
CN114761569A (zh) * 2019-10-16 2022-07-15 康奈尔大学 阿尔茨海默氏病的基因疗法
US20250270547A1 (en) * 2020-02-28 2025-08-28 Rznomics Inc. Trans-splicing ribozyme specific to apoe4 rna and use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
JPH04507041A (ja) 1988-12-13 1992-12-10 アメリカ合衆国 遺伝工学により修飾された内皮細胞およびその利用方法
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
JPH06500923A (ja) 1990-09-21 1994-01-27 カイロン　コーポレイション パッケージング細胞
JP3418982B2 (ja) 1990-10-31 2003-06-23 ソマティクス セラピー コーポレイション 内皮細胞の遺伝的変性
WO1992014829A1 (en) 1991-02-19 1992-09-03 The Regents Of The University Of California Viral particles having altered host range
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU6714094A (en) 1993-04-28 1994-11-21 Ribozyme Pharmaceuticals, Inc. Ocular delivery of nucleic acid
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
EP0961830A1 (en) * 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
US6034072A (en) 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
AU8476698A (en) 1997-07-03 1999-01-25 Osiris Therapeutics, Inc. Human mesenchymal stem cells from peripheral blood
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO2002007774A2 (en) * 2000-07-19 2002-01-31 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
WO2000004050A2 (en) 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
RU2238947C2 (ru) 1998-07-14 2004-10-27 Янссен Фармацевтика Н.В. Нейротрофический фактор роста человека (эновин), кодирующая его выделенная молекула нуклеиновой кислоты, вектор (варианты), фармацевтическая композиция (варианты), антитело, способ обнаружения фактора роста, набор, способ идентификации агониста или антагониста (варианты)
CA2407074A1 (en) 2000-04-21 2001-11-01 Jukka Hartikka Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
EP2301552A1 (en) * 2001-11-21 2011-03-30 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
GB0212648D0 (en) * 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
US20060073119A1 (en) * 2004-09-01 2006-04-06 Avigen, Inc. Methods for treating neurodegenerative disorders
US20080025962A1 (en) * 2004-11-30 2008-01-31 Angesmg,Inc. Remedy for Alzheimer's Disease
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
CA2654033A1 (en) * 2006-05-31 2007-12-06 Dnavec Corporation Therapeutic agent for alzheimer's disease

Also Published As

Publication number Publication date
CN101652063A (zh) 2010-02-17
CN106890342B (zh) 2022-09-23
EP2114153A2 (en) 2009-11-11
CA2677273A1 (en) 2008-08-14
RU2009132196A (ru) 2011-03-20
US20080292603A1 (en) 2008-11-27
EP2114153A4 (en) 2011-05-11
KR20140102327A (ko) 2014-08-21
RU2471487C2 (ru) 2013-01-10
WO2008097927A3 (en) 2008-12-18
AU2008213999A1 (en) 2008-08-14
JP5829377B2 (ja) 2015-12-09
NZ579050A (en) 2012-10-26
US20130231632A1 (en) 2013-09-05
ZA200906165B (en) 2012-02-29
KR20090118956A (ko) 2009-11-18
JP2010518105A (ja) 2010-05-27
AU2008213999B2 (en) 2014-04-17
IL200151A (en) 2015-06-30
CN106890342A (zh) 2017-06-27
IL200151A0 (en) 2010-04-15
EP2114153B1 (en) 2016-11-23
WO2008097927A2 (en) 2008-08-14
KR101661356B1 (ko) 2016-09-30
US8247385B2 (en) 2012-08-21

Similar Documents

Publication Publication Date Title
MX2009008413A (es) Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica.
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
WO2017191274A3 (en) Rna encoding a therapeutic protein
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MX2019001920A (es) Arn la terapia contra el cancer.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
EA201591281A1 (ru) Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
TW200744642A (en) Novel peptides for use in the treatment of obesity
IN2015DN00376A (es)
MX2011012311A (es) Marcadores geneticos asociados con la respuesta al interferon alfa.
WO2008087186A3 (en) Peptides for use in the treatment of obesity
IN2014DN06920A (es)
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
IL191796A0 (en) Combination of zd6474 and pemetrexed
WO2008087188A3 (en) Peptides for use in the treatment of obesity
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
MX2018015110A (es) Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos.
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
MX2024014216A (es) Compuestos aromaticos que contienen boro y analogos de insulina relacionados

Legal Events

Date Code Title Description
FG Grant or registration